anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The present invention relates to nanometer toothpaste. The prior nanometer toothpaste has high cost and large undulation of a sterilization effect. A technical problem for the present invention to solve is how to conquer the above disadvantages of the prior nanometer toothpaste to provide nanometer toothpaste, which is provided with low cost, stable sterilization effect and can be used for curing dental diseases. In order to solve the above technical problem, the nanometer toothpaste of the present invention contains a nanometer grade TiO&lt;SUB&gt;2&lt;/SUB&gt;, an adhesive, a vesicant, a wetting agent and water, wherein the nanometer grade TiO&lt;SUB&gt;2&lt;/SUB&gt; takes 3 to 17 percent of the total weight. The special character of the present invention lies in that the present invention also includes a nanometer silver-loaded bactericide which takes 1 to 50 percent of the total weight. After adopting the above technical proposal, the nanometer toothpaste of the present invention has the advantages of the low cost, stable sterilization effect and being able to be used for preventing decayed tooth and is an ideal regenerate product of the prior medical toothpaste.
Artificial dentures and dental plates are obtained by filling dental moulds, prepared in the usual manner, with a highly viscous but flowable composition consisting wholly or largely of one or more of the unsaturated organic substances in monomeric or partially polymerized condition, and subjecting the composition to polymerization.  The polymerization may be effected by warming the moulds at temperatures at which bubble formation does not occur; or may be carried out more quickly at higher temperatures in an autoclave under gas pressure.  Known polymerization catalysts, e.g. hydrogen peroxide and benzoyl peroxide, and regulators, e.g. turpentine oil may be employed.  Additions such as artificial and natural resins, cellulose derivatives, e.g. cellulose tripropionate and cellulose ethers, softeners, dyestuffs and fillers may be employed.  The desired viscous condition is obtained by partial polymerization or by dissolving substances, e.g. cellulose derivatives in the monomer.  Gypsum moulds are coated with a film of water-glass, gelatine, polyvinyl alcohol, sodium polyacrylate, &amp;c. to facilitate release of the finished article.  In examples, a gypsum mould, coated with gelatine, is filled with a mixture of (1) methacrylic acid methyl ester and acrylic acid butyl ester together with benzoyl peroxide, red dyestuff and white pigment, (2) methacrylic acid ethyl ester and cellulose tripropionate, and (3) acrylic acid ethyl ester, acrylic acid nitrile, vinyl acetate and methacrylic acid methyl ester.ALSO:Artificial dentures and dental plates are obtained by filling dental moulds, prepared in the usual manner, with a highly viscous but flowable composition consisting wholly or largely of one or more of the unsaturated organic substances in monomeric or partially polymerized condition, and subjecting the composition to polymerization, e.g. by warming the moulds at temperatures at which bubble formation does not occur or at higher temperatures under gas pressure.  Gypsum moulds are coated with a film of water-glass, gelatine, polyvinyl alcohol, sodium polyacrylate, &amp;c. to facilitate release of the finished article.
In a body pack, preferably a face pack (1), small permanent magnets (3) having at least one north pole and one south pole are embedded in the binder composition (2). The permanent magnets (3) may have an irregular, disc-shaped, lentil-shaped or oval configuration and have a diameter of 2-10 mm. They are made of sintered or plastic-bound barium and/or strontium ferrite by compression, injection moulding or extrusion. The binder composition (2) has a consistency of high viscosity and contains cosmetic substances as well as completely or partially hardening substances, e.g. gypsum or clay. &lt;IMAGE&gt;
Transplantation is one of the most challenging and complex areas of medicine, and involves the transfer of a tissue or organ from a donor to a recipient patient. Rejection arises due to sensitisation of the cell-mediated immune system of the recipient to the foreign (allogeneic) antigens of the donor. In particular, the recipient&#39;s immune system reacts to the major histocompatibility complex (MHC) molecules presented on the surface of the donor tissues (the graft). In this context, there is an interest to produce anti-HLA-A2 chimeric antigen receptors (CARs) to create alloantigen-specific Tregs that can be highly suitable in transplantation. The inventors have now isolated an anti-HLA-A2 human monoclonal antibody (named as &#34;A2Ab&#34;) of low affinity (10 -6  M) and performed an affinity maturation in of said antibody. Said antibodies would be very suitable for generating CAR-Treg cells. Accordingly, the present invention relates to human monoclonal antibodies binding to HLA-A2.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a highly safe and inexpensive anti-aging agent derived from natural products and having high productivity and excellent I type collagen production promoting actions, fibroblast proliferating actions or laminin 5 production promoting actions though daily usable.  &lt;P&gt;SOLUTION: The anti-aging agent is characterized by comprising at least any of Gynura bicolor DC. and an extract thereof as an active ingredient. The extract of the Gynura bicolor DC. is preferably an extract with a mixed solvent of water and ethanol. The type I collagen production promoter is characterized by comprising at least any of the Gynura bicolor DC. and the extract thereof as the active ingredient. The fibroblast proliferation agent is characterized by comprising at least any of the Gynura bicolor DC. and the extract thereof as the active ingredient. The laminin 5 production promoter is characterized by comprising at least any of the Gynura bicolor DC. and the extract thereof as the active ingredient. An external preparation for skin comprises the anti-aging agent and a food and drink for beauty comprises the anti-aging agent.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The invention provides a Jianqu and a preparation method of the Jianqu. Aims to solve the technical problem of slow fermentation speed in the prior art for preparing the Jian qu. The adopted technical scheme is as follows: the preparation method of the Jianqu comprises the following steps: crushing and uniformly mixing the raw materials to prepare a fermentation substrate, and sterilizing the fermentation substrate; uniformly mixing the composite microbial inoculum and the sterilized fermentation substrate, and preparing the mixture into blocks for fermentation; and after fermenting for 35-45 hours, taking out a fermentation product and drying to obtain the Jian Qu. Wherein the raw materials comprise: polygonum hydropiper, Xanthium sibiricum, sweet wormwood, bitter apricot seed, red bean, malt and the like. Wherein, the complex microbial inoculum comprises: powdery Mueller&#39;s yeast, Rhizomucor miehei, transverse pedunculus mycorrhiza, Monascus purpureus, Saccharomycopsis fibuligera, and Pichia bartoniensis. In addition, the invention also provides the Jian Qu prepared by the preparation method.
A composition and method for affixing a dental appliance to the teeth characterized by effecting a layer of catalyst that will effect polymerization of a bonding resin on the surface of the teeth to which the dental appliance is to be affixed, after the surface has been cleaned and dried so as to effect a good bond; effecting a layer of the catalyst on the base of at least a portion of the dental appliance that is to be bonded to the teeth after the base has been cleaned and dried so as to effect a good bond; positioning the base of the portion of the dental appliance adjacent the teeth after resin has been applied intermediate the two layers of catalyst on the base and on the surface of the tooth. After a predetermined cure time, the remainder of the dental appliance is affixed in place. The bonding resin is selected from the group consisting of epoxy, per se or capped with hydrolysis-resistant moiety; urethane; cyano-acrylate; methacrylate; vinyl ester; and acrylate. Appropriate catalyst such as benzoyl peroxide and initiator are preferably employed for effecting polymerization. Also, critical viscosity of the bonding resin in the range of 25,000-40,000 centipoises, as measured with a Brookfield Niscometer at 50° C., is employed, with filler if necessary, to obtain the desired wettability and prevent &#34;creep&#34; during gellation. Also disclosed are preferred constituents and steps in the method, including the indirect bonding method.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide radio-opaque polymers which degrade through a main polymer chains derived from tyrosine.  &lt;P&gt;SOLUTION: Iodinated and/or brominated derivatives of aromatic dihydroxy monomers are produced and polymerized to form radio-opaque polymers. The monomers may also be copolymerized with other dihydroxy monomers. The iodinated and brominated aromatic dihydroxy polymers can be employed as radio-opacifying, biocompatible non-toxic additives for other polymeric biocompatible materials. Radio-opaque medical implants and drug delivery devices for implantation produced from the polymers are also disclosed.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a recombinant preduodenal lipase and a peptide derivative produced by a transformed plant; and to provide a process for obtaining them and applications thereof.  &lt;P&gt;SOLUTION: A recombinant nucleotide sequence containing a cDNA encoding canine or human preduodenal lipase is obtained. A plant cell (especially, Nicotiana tabacum of a plant of Solanaceae) is transformed by using the recombinant nucleotide sequence, and further a transformed plant is obtained. The preduodenal lipase is obtained by an extraction process therefrom. The lipase is applied as a constituent component for a medical composition, a functional food or the like.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
A medical condition quantification and dysfunction-reduction therapy evaluation process enables a health care service provider to monitor the improvement of a patient&#39;s condition, as well as the efficiency of the rehabilitation process employed to achieve a patient improvement objective. Based upon initial patient examination data, one or more sets of parameters associated with respective body regions, for which dysfunction-reducing therapy is to be carried out, are provided. For each parameter, a data value is generated. The magnitude of the data value is based upon the condition of the body region associated with the parameter. All of the data values of the parameters of a body region are combined, to quantify the overall condition or dysfunction of the body region. Periodically, during the course of the patient therapy program, the physical condition of the body region being treated is re-examined. Based upon each re-examination, the numerical data value of each parameter is updated to reflect the current condition of body region, and the updated values are combined to thereby quantify the current dysfunction of the body region being treated. By graphically recording both the original quantification of the dysfunction and the iteratively updated quantification results of the therapy session, the progress of the patient therapy program in reducing dysfunction of the body region can be readily tracked, so as to enable the health care service provider to monitor whether the therapy is reducing the dysfunction, and how efficiently it is doing so.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a therapeutic preparation which is an antagonist or partial agonist of human interleukin-4.  &lt;P&gt;SOLUTION: This therapeutic preparation is the antagonist or partial agonist of the human interleukin-4 or contains the antagonist or partial agonist, wherein the antagonist or partial agonist is a human mutant interleukin-4 protein. The selection of the therapeutic preparation is carried out in a standardized form by a genetic industrial method. A protein competing with the human mutant interleukin-4 in relation to the occupation of human mutant interleukin-4 receptor due to the resemblance to wild type human mutant interleukin-4 can be produced. The human mutant interleukin-4 protein, and the method for producing the same.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
ABSTRACT OF THE DISCLOSURE The present invention relates to nucleic acid sequences encoding ciliary neurotrophic factor (CNTF) and to the proteins, peptides, and derivatives produced therefrom. In various embodiments of the invention, the nucleic acid sequences, proteins, and peptides of the invention may be used in the treatment of a variety of neurological diseases and disorders, including Alzheimer&#39;s disease. In a specific embodiment of the invention, CNTF may be used to support the growth of spinal cord neurons, thereby providing a method of treating spinal cord damage caused by trauma infarction, infection, nutritional deficiency or toxic agents. The present invention also relates to a novel method for producing substantially pure CNTF. The invention also relates to pharmacuetical compositions comprising effective amounts of CNTF gene products which may be used in the diagnosis and treatment of a variety of neurological diseases and disorders. The present invention relates to the cloning sequencing and expression of CNTF and provides, for the first time, a means for producing human CNTF utilizing human CNTF-encoding nucleic acid sequences. Furthermore, the CNTF nucleic acid sequences of the invention may be utilized to identify nucleic acid sequences encoding CNTF or CNTF-homologous molecules in a variety of species and tissues.
FIELD: medicine, may be used in conducting procedures in bath houses of different kinds, solarium etc. SUBSTANCE: method involves using biologically active extracts, such as Auron, Vitaon, Somaton; determining frequency of application and/or inhalation of balms on the basis of functional state of organism. Auron is applied to head skin, Vitaon - to mucous membranes and face and Somaton to user&#39;s body. Thermal-hydrotherapeutical procedures are conducted at temperature of 25-115 C and relative humidity of 10-100%. EFFECT: increased efficiency in healthening of individual&#39;s organism, protecting from overheating, increasing sweating, improved electrolytic blood content and energetic potential. 4 cl
PURPOSE:To provide an antithrombocytic agent containing 24,25-dihydrocholecalciferol as an active component, having antithrombocytic activity with low side effects, and useful for the treatment of cerebrovascular diseases, ischemic cardiopathy, etc. CONSTITUTION:The objective antithrombocytic agent contains 24,25-dihydroxycholecalciferol (abbreviated as the present substance) of e.g. formula I . The present substance has been already known to have antihypercalcemic and antitumor activities, etc., however, it has been newly found that the compound also has antithromobocytic activity. The present substance is preferably 24R,25-(OH)2- D3 of formula II. In contrast with the activated vitamin D3 analog, the present substance has extremely high safety. Dose: preferably 0.5-1X10&lt;4&gt;mug/day for the treatment of thromobosis, capillaropathy, hyperthrombocytosis, etc. as an antithrombotic agent.
PURPOSE: To use the 1,4-dihydropyridine, more particularly nimodipin, having a calcium antagonism effect to suppress neural diseases and more particularly peripheral neural diseases caused by diabetes mellitus. CONSTITUTION: The calcium antagonists selected from 1,4-dihydropyridine homologues and more particularly nimodipin [1,4-dihydro-2,6-dimethyl-4-(3&#39;- nitropheyl)pyridine-3-β-methoxyethyl ester 5-isopropyl ester] are used in production of the medicine for suppressing the neural diseases caused by the diabetes mellitus. This medicine antagonizes the disorders of the sensory peripheral nerves and motor peripheral nerves of the type which occur most frequently among the squeals of the diabetes mellitus and is useful as the treating agent for the same. The active material, such as nimodipin, is extended by a solvent or excipient and is then prepd. by conversion to a tablet, coated tablet, granule, syrup agent, emulsion, suspension, soln., etc., by using assistants suitable for inert and nontoxic medicines.  The oral administration is preferable and the dosage of 0.1 to 10 mg/kg is recommended.
An electronic system is featured to enable a radiological image archiving system supplier to provide a customer with economic data regarding a supplier&#39;s radiological image archiving system. The system is operable to direct a query page to the customer via an electronic communication system. The query page provides the customer with at least one question. The at least one question is designed so that the answer(s) to the at least one question enables the system to establish expected cost reductions resulting from the use of the supplier&#39;s radiological image archiving system over the use of the customer&#39;s existing archival system. The answer(s) also may be used to enable the system to establish a recommended radiological image archiving system for the customer. The answer(s) also may be used to establish a payback period for the recommended radiological image archiving system based on the expected cost reductions resulting from the use of the supplier&#39;s radiological image archiving system and the cost of the recommended system.
Use of a paramyxovirus vector makes it possible to transfer a nucleic acid into a blood vessel at a high efficiency even by exposing to the vector with in a short period of time. Namely, a paramyxovirus vector to be used for transferring a nucleic acid into vascular cells and a nucleic acid transfer method with the use of this virus vector are provided. The gene transfer efficiency into the vascular media layer is significantly elevated by treati ng the blood vessel with a protease. The expression of the transferred gene remains stable over a long time in the vascular cells. Use of this method makes it possible to efficiently transfer a gene within a short period of ti me into the vascular cavity, media, tunica tissues, etc. in gene therapy.&lt;/SDOA B&gt;
NEW MATERIAL:The compound of formula I {R is lower alkyl or lower alkoxy; A is tetrahydro-3-pyridyl, 3-pyridyl, etc. which may be substituted at the N atom with (lower alkoxy-substituted) lower alkyl or group of R&lt;1&gt;-NHCO- [R&lt;1&gt; is H, lower alkyl or (substituted) phenyl]} and its acid addition salt. EXAMPLE:2-Methyl-3-nicotinoylpyrazolo[1,5-a]pyridine. USE:Agent for suppressing the coagulation of blood platelet. It is useful e.g. for the prevention and remedy of cerebral circulation diseases, arterial diseases, thrombosis, cardiac diseases, local amenic fit, migrane, cancer, and arterial complication of the patient of diabetes. PREPARATION:The compound of formula II is made to react with the compound of formula III (X is reactive eliminable group) or its acid addition salt optionally in a solvent such as nitrobenzene at room temperature - 200 deg.C.
The non-receptor tyrosine kinase activity of fusion gene Bcr-Abl derived oncoproteins is the key factors responsible for development and progress of Philadelphia positive (Ph+) Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL). In the search for a peptide-based inhibitor of Bcr- Abl tyrosine kinase, here we investigated a naturally occurring molecule called Apoptin. &#39;Apoptin1 is a 14 kDa viral protein (chicken anemia virus protein-3, CAV- VP3) and known to induce apoptosis in a wide range of transformed but not in primary cells. During the initial phase of our study an array-based analysis demonstrated that Apoptin interacts with the SH3 domain of AbI. We further investigated the role of Apoptin on Bcr-Abl. High stringent pul!-down and co- immunoprecipitation assays revealed that Apoptin strongly interacts with the fusion protein Bcr-Abl (p210). We also identified Apoptin&#39;s ability to significantly inhibit Bcr-Abl kinase and presumably indirectly a series of downstream targets (e.g. CrkL, STATS, c-Myc, etc.). In comparison studies, using lmatinib® we discovered that apoptin has a significant killing efficacy on human and mouse CML celi lines expressing Bcr-Abl. We postulated, the interacting segment of the Apoptin molecule acts as an adaptor and negatively regulates the Bcr-Abl kinase. The obtained data provides foundation for the development of peptide based tyrosine kinase inhibitors as new anti-cancer agents.
PROBLEM TO BE SOLVED: To obtain a dermal external agent having excellent functional characteristic and a dampness keeping property by including a vegetable squalane containing a specific amount of isoparaffin fraction having a specific melting point. SOLUTION: This dermal external agent is obtained by subjecting a vegetable oil (e.g. soybean oil or a germ oil) to hydrogenation and fractionating extraction and contains a vegetable squalane containing &gt;=5 wt.% of isoparaffin fraction having 25-40 deg.C melting point in an amount of preferably 0.01-100 wt.% based on a total weight of the composition. As a use shape of the external agent, e.g. an ointment, a cream, a lotion, a latex, a pack or a cosmetic oil is preferably exemplified. Further, as an oil agent mixed with the objective external agent, a known external base agent, e.g. a silicone oil such as methylphenylpolysiloxane or hydrocarbons such as paraffin can be used other than the squalane.
PURPOSE: To obtain such a compsn., containing a specified aldobionamide including β-galactoside bonds as a dental antiplawque agent, that shows such a dental antiplaque effect that an antimicronbial agent decays the bond or effect of microbes, and that can be handled in a commercial scale. CONSTITUTION: This oral hygienic compsn. contains a compd. as a dental antiplaque drug having at least one β-galactoside bond and selected from aldobionamide containing a part expressed by formula I and corresponding ammonium salt of the aldobionic acid. The compd. is incorporated in an effective amt. to inhibit dental plaque. In formula I, R&lt;1&gt; , R&lt;2&gt; are each H, aliphatic hydrocarbon, aromatic, alicyclic groups or aminoacid esters. As for the aldobionamide as an dental antiplaque agent, for example, lactobionamide expressed by formula II can be used. The compd. of the formula II can be obtd. at a low cost from lactobiono-1,5-lactone produced from lactobionic acid derived from lactose.
PURPOSE:To obtain the title additive with its degradation in the first stomach prevented to the utmost, excellent in the absorption efficiency in the digestive organs, namely the fourth stomach and the succeeding organs by coating a biologically active substance-contg. core material with a specific copolymer- contg. coating agent. CONSTITUTION:A binder, shaping agent, etc., are applied on biologically active substance(s) such as amino acid(s) and its derivative(s), vitamins or veterinary medicine(s) to make a granulation and drying to prepare a core material. Thence, a 4-vinylpyridine-styrene copolymer &gt;=0.5dl/g in reduced viscosity produced by pref. radical polymerization of 4-vinylpyridine and styrene at the weight ratio = (60:40)-(85:15) [pref. (65:35)-(80:20)] is dissolved in a solvent such as methylene chloride and, if needed, incorporated with e.g. inorganic powder such as talc as coagulation preventive [at the weight ratio of the copolymer to the powder = (1:4)-(5:1)]. The surface of said core material is then coated with the resulting liquid by e.g. fluidized coating process, thus obtaining the objective additive.